Unknown

Dataset Information

0

Long-Term Survival and Failure Outcomes of Single-Fraction Stereotactic Body Radiation Therapy in Early Stage NSCLC.


ABSTRACT:

Introduction

This study aims to report our 13-year institutional experience with single-fraction stereotactic body radiation therapy (SF-SBRT) for early stage NSCLC.

Methods

A single-institutional retrospective review of patients with biopsy-proven peripheral cT1-2N0M0 NSCLC undergoing definitive SF-SBRT between September 2008 and May 2022 was performed. All patients were treated to 27 Gy with heterogeneity corrections or 30 Gy without. Primary outcomes were overall survival and progression-free survival. Secondary outcomes included local failure, nodal failure, distant failure, and second primary lung cancer.

Results

Among 263 eligible patients, the median age was 76 years (interquartile range [IQR]: 70-81 y) and median follow-up time was 27.2 months (IQR: 14.25-44.9 mo). Median tumor size was 1.9 cm (IQR: 1.4-2.6 cm), and 224 (85%) tumors were T1. There were 92 patients (35%) alive at the time of analysis with a median follow-up of 34.0 months (IQR: 16.6-50.0 mo). Two- and five-year overall survival was 65% and 26%, respectively. A total of 74 patients (28%) developed disease progression. Rates of five-year local failure, nodal failure, distant failure, and second primary lung cancer were 12.7%, 14.7%, 23.5%, and 12.0%, respectively.

Conclusions

Consistent with multiple prospective randomized trials, in a large real-world retrospective cohort, SF-SBRT for peripheral early stage NSCLC was an effective treatment approach.

SUBMITTER: Iovoli AJ 

PROVIDER: S-EPMC10730364 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Long-Term Survival and Failure Outcomes of Single-Fraction Stereotactic Body Radiation Therapy in Early Stage NSCLC.

Iovoli Austin J AJ   Prasad Sharan S   Ma Sung Jun SJ   Fekrmandi Fatemeh F   Malik Nadia K NK   Fung-Kee-Fung Simon S   Farrugia Mark K MK   Singh Anurag K AK  

JTO clinical and research reports 20231102 12


<h4>Introduction</h4>This study aims to report our 13-year institutional experience with single-fraction stereotactic body radiation therapy (SF-SBRT) for early stage NSCLC.<h4>Methods</h4>A single-institutional retrospective review of patients with biopsy-proven peripheral cT1-2N0M0 NSCLC undergoing definitive SF-SBRT between September 2008 and May 2022 was performed. All patients were treated to 27 Gy with heterogeneity corrections or 30 Gy without. Primary outcomes were overall survival and p  ...[more]

Similar Datasets

| S-EPMC6236177 | biostudies-other
| S-EPMC6488937 | biostudies-literature
| S-EPMC6508090 | biostudies-literature
| S-EPMC7560377 | biostudies-literature
| S-EPMC6162523 | biostudies-other
| S-EPMC8717953 | biostudies-literature
| S-EPMC6123192 | biostudies-other
| S-EPMC10807683 | biostudies-literature
| S-EPMC6902813 | biostudies-literature
| S-EPMC9307906 | biostudies-literature